HOPE SPV receives US$819,000 second tranche of funding
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Zelira Therapeutics Ltd. has announced the receipt of a second tranche of funding for its HOPE® SPV, amounting to a significant sum from the Forman Trust. To date, the total funds received by the HOPE® SPV have reached a notable amount, enhancing Zelira's financial backing for its clinical programs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- September 2023 Quarterly Activities Report
- Zelira closes $3.25M funding as part of HOPE SPV fundraise
- June 2023 Quarterly Activities Report
- Zeliras diabetic nerve pain drug outperforms Lyrica
- Trading Halt
Later from Zelira Therapeutics
- December 2023 Quarterly Activities Report
- Appendix 4D & FY24 Interim Financial Report
- Zelira receives $919,000 R&D Tax Incentive Scheme Refund
- March 2024 Quarterly Activities Report
- HOPE SPV receives US$681,000 third tranche of funding
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics